Journal article

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas

Michael S Anglesio, Stefan Kommoss, Mary C Tolcher, Blaise Clarke, Laura Galletta, Henry Porter, Sambasivarao Damaraju, Sian Fereday, Boris J Winterhoff, Steve E Kalloger, Janine Senz, Winnie Yang, Helen Steed, Ghassan Allo, Sarah Ferguson, Patricia Shaw, Attila Teoman, Joaquin J Garcia, John K Schoolmeester, Jamie Bakkum-Gamez Show all



Mucinous ovarian carcinomas (MCs) typically do not respond to current conventional therapy. We have previously demonstrated amplification of HER2 in 6 of 33 (18.2%) mucinous ovarian carcinomas (MCs) and presented anecdotal evidence of response with HER2-targeted treatment in a small series of women with recurrent HER2-amplified (HER2+) MC. Here, we explore HER2 amplification and KRAS mutation status in an independent cohort of 189 MCs and 199 mucinous borderline ovarian tumours (MBOTs) and their association to clinicopathological features. HER2 status was assessed by immunohistochemistry (IHC), FISH, and CISH, and interpreted per ASCO/CAP guidelines, with intratumoural heterogeneity assessme..

View full abstract


Awarded by US Army Medical Research and Material Command


Funding Acknowledgements

We wish to thank the collaborating centres, including the Mayo Clinic (initiated by Dr Rita Wang), the Australian Ovarian Cancer Study Group (AOCS), the Toronto centres of Princess Margaret Hospital and Toronto General, and the Alberta Cancer Research Biorepository/Canadian Breast Cancer Foundation Tumor Bank at Alberta Health Services (AHS), as well as British Columbia's Ovarian Cancer Research group (OvCaRe), for contributions of biospecimen, clinical, and outcome data, as well as intellectual contributions. Funding to OvCaRe for this project was provided for by the Terry Fox Research Institute and Canadian Institutes for Health Research Emerging Team Grant in the Genomics of Forme Fruste Tumours: New Vistas on Cancer Biology and Management, the British Columbia Cancer Foundation, and the Vancouver General Hospital-University of British Columbia Hospital Foundation. In addition, the AOCS thanks the study nurses and research assistants for their contribution and all of the women who participated in the study ( The AOCS is approved by the Human Research Ethics Committees at the Peter MacCallum Cancer Centre, Queensland Institute for Medical Research and all participating hospitals. The Australian Ovarian Cancer Study was supported by the US Army Medical Research and Material Command under DAMD17-01-1-0729, Cancer Council Victoria, Queensland Cancer Fund, Cancer Council New South Wales, Cancer Council South Australia, Cancer Foundation of Western Australia, Cancer Council Tasmania, and the National Health and Medical Research Council of Australia (NHMRC).